EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.

Mahmut Gumus,Caglayan Geredeli,Mahmut Ucar,Serap Kaya,Hacer Demir,Olcun Umit Unal,Mustafa Değirmenci,Gamze Gokoz Dogu,Nedim Turan,Nilgun Yildirim,Fatma Buğdaycı Başal,Erkan Arpaci,Mustafa Karaağaç,Hakan Harputluoglu,Haci Mehmet Türk,Faysal Dane,Metin Ozkan

EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.

2017

Mahmut Gumus
Caglayan Geredeli
Mahmut Ucar
Serap Kaya
Hacer Demir
Olcun Umit Unal
Mustafa Değirmenci
Gamze Gokoz Dogu
Nedim Turan
Nilgun Yildirim
Fatma Buğdaycı Başal
Erkan Arpaci
Mustafa Karaağaç
Hakan Harputluoglu
Haci Mehmet Türk
Faysal Dane
Metin Ozkan

e15028Background: Overall survival times have been exceeded three years by the targeted treatments in metastatic colorectal cancer (MCC) . The sequence of these agents and the possible side effects...

Keywords:

Cancer research
Pathology
Colorectal cancer
Panitumumab
Medicine
in patient
overall survival
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations